Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database

被引：0
|
作者：
Megan C. Roberts
Dave P. Miller
Steven Shak
Valentina I. Petkov
机构：
[1] National Cancer Institute,
[2] Genomic Health Inc.,undefined
来源：
Breast Cancer Research and Treatment | 2017年 / 163卷
关键词：
Breast cancer; Disease-specific survival; Lymph node-positive; Oncotype DX; Recurrence Score; SEER;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：303 / 310
页数：7
相关论文
共 50 条
  • [21] The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients
    Stemmer, Salomon M.
    Klang, Shmuel H.
    Ben-Baruch, Noa
    Geffen, David B.
    Steiner, Mariana
    Soussan-Gutman, Lior
    Merling, Shahar
    Svedman, Christer
    Rizel, Shulamith
    Lieberman, Nicky
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 140 (01) : 83 - 92
  • [22] Nomograms predict survival of patients with lymph node-positive, luminal a breast cancer
    Yilun Li
    Li Ma
    BMC Cancer, 21
  • [23] Nomograms predict survival of patients with lymph node-positive, luminal a breast cancer
    Li, Yilun
    Ma, Li
    BMC CANCER, 2021, 21 (01)
  • [24] Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer
    Kyoko Yorozuya
    Toru Takeuchi
    Miwa Yoshida
    Yukako Mouri
    Junko Kousaka
    Kimihito Fujii
    Shogo Nakano
    Takashi Fukutomi
    Kazuo Hara
    Shu Ichihara
    Yingsong Lin
    Shogo Kikuchi
    Journal of Cancer Research and Clinical Oncology, 2010, 136 : 939 - 944
  • [25] Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer
    Yorozuya, Kyoko
    Takeuchi, Toru
    Yoshida, Miwa
    Mouri, Yukako
    Kousaka, Junko
    Fujii, Kimihito
    Nakano, Shogo
    Fukutomi, Takashi
    Hara, Kazuo
    Ichihara, Shu
    Lin, Yingsong
    Kikuchi, Shogo
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (06) : 939 - 944
  • [26] Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer
    Halpern, Naama
    Sonnenblick, Amir
    Uziely, Beatrice
    Divinsky, Luba
    Goldberg, Yael
    Hamburger, Tamar
    Peretz, Tamar
    Kadouri, Luna
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (09) : 2145 - 2149
  • [27] Development and Validation of a Prognostic Nomogram for Predicting Cancer-Specific Survival in Patients With Lymph Node Positive Bladder Cancer: A Study Based on SEER Database
    Zhan, Xiangpeng
    Jiang, Ming
    Deng, Wen
    Liu, Xiaoqiang
    Chen, Luyao
    Fu, Bin
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [28] Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer
    Tan, Aaron C.
    Li, Bob T.
    Nahar, Kazi
    Danieletto, Suzanne
    Fong, Eva S.
    Currer, Trevor
    Parasyn, Andrew
    Middleton, Philip
    Wong, Heidi
    Smart, Denis
    Rutovitz, Josie J.
    McCloud, Philip
    Hughes, T. Michael
    Marx, Gavin M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (02) : E161 - E166
  • [29] Association between Oncotype DX recurrence score and dynamic contrast-enhanced MRI features in patients with estrogen receptor-positive HER2-negative invasive breast cancer
    Kim, Hee Jeong
    Choi, Woo Jung
    Kim, Hak Hee
    Cha, Joo Hee
    Shin, Hee Jung
    Chae, Eun Young
    CLINICAL IMAGING, 2021, 75 : 131 - 137
  • [30] Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer
    Andrew Dodson
    David Okonji
    Laura Assersohn
    Anne Rigg
    Amna Sheri
    Nick Turner
    Ian Smith
    Marina Parton
    Mitch Dowsett
    Breast Cancer Research and Treatment, 2018, 168 : 249 - 258
12345